TY - JOUR
T1 - Metastasizing intramucosal gastric carcinomas. Well differentiated type and proliferative activity using proliferative cell nuclear antigen and Ki‐67
AU - Oya, Masafumi
AU - Yao, Takashi
AU - Nagai, Eishi
AU - Tsuneyoshi, Masazumi
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1995/2/15
Y1 - 1995/2/15
N2 - Background. Recently, endoscopic surgery for small superficial gastric carcinomas has become increasingly more challenging, and the treatment criteria remain controversial. Methods. To examine the metastatic potential of intramucosal gastric cancers (IMGCs), IMGCs with regional lymph node involvement (NI) were compared with IMGCs without regional lymph NI clinicopathologically. To clarify the metastatic behavior of well differentiated adenocarcinoma (W‐type), immunohistochemical staining using Ki‐67 and proliferating cell nuclear antigen (PCNA) monoclonal antibodies were performed. Results. Of the 943 lesions with IMGC, 21 (2.2%) were NI on histologic examination. There was no significant difference between the macroscopic classification and the incidence of NI. The sizes of the IMGCs with NI (median, 4.3 cm) were significantly larger than the IMGCs without NI (median, 2.4 cm). Among the histologic grades classified according to the predominant features, the incidence of NI in poorly differentiated adenocarcinoma (P‐type) (12/304, 3.9%) was significantly higher than that in well differentiated (W‐type) (6/489, 1.2%). Besides the 12 P‐type IMGCs, 6 well and moderately differentiated type IMGCs contained some poorly differentiated components, totaling 18 IMGCs (86%) that were either mainly or partially P‐type. Among the W‐type IMGCs, the mean values of the Ki‐67 and PCNA labeling indices (LI) for IMGCs with NI (Ki‐67, 47.5%; PCNA, 58.3%) were higher than those of the 25 randomly selected IMGCs without NI (Ki‐67, 39.2%; PCNA, 39.9%). Conclusions. The potential for NI in IMGCs seems to be related closely to tumor size, the presence of poorly differentiated components, and, particularly in the W‐type IMGC, the LI that are demonstrated immunohistochemically with Ki‐67 and/or PCNA. Cancer 1995;75:926‐35.
AB - Background. Recently, endoscopic surgery for small superficial gastric carcinomas has become increasingly more challenging, and the treatment criteria remain controversial. Methods. To examine the metastatic potential of intramucosal gastric cancers (IMGCs), IMGCs with regional lymph node involvement (NI) were compared with IMGCs without regional lymph NI clinicopathologically. To clarify the metastatic behavior of well differentiated adenocarcinoma (W‐type), immunohistochemical staining using Ki‐67 and proliferating cell nuclear antigen (PCNA) monoclonal antibodies were performed. Results. Of the 943 lesions with IMGC, 21 (2.2%) were NI on histologic examination. There was no significant difference between the macroscopic classification and the incidence of NI. The sizes of the IMGCs with NI (median, 4.3 cm) were significantly larger than the IMGCs without NI (median, 2.4 cm). Among the histologic grades classified according to the predominant features, the incidence of NI in poorly differentiated adenocarcinoma (P‐type) (12/304, 3.9%) was significantly higher than that in well differentiated (W‐type) (6/489, 1.2%). Besides the 12 P‐type IMGCs, 6 well and moderately differentiated type IMGCs contained some poorly differentiated components, totaling 18 IMGCs (86%) that were either mainly or partially P‐type. Among the W‐type IMGCs, the mean values of the Ki‐67 and PCNA labeling indices (LI) for IMGCs with NI (Ki‐67, 47.5%; PCNA, 58.3%) were higher than those of the 25 randomly selected IMGCs without NI (Ki‐67, 39.2%; PCNA, 39.9%). Conclusions. The potential for NI in IMGCs seems to be related closely to tumor size, the presence of poorly differentiated components, and, particularly in the W‐type IMGC, the LI that are demonstrated immunohistochemically with Ki‐67 and/or PCNA. Cancer 1995;75:926‐35.
UR - http://www.scopus.com/inward/record.url?scp=0028801433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028801433&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19950215)75:4<926::AID-CNCR2820750406>3.0.CO;2-U
DO - 10.1002/1097-0142(19950215)75:4<926::AID-CNCR2820750406>3.0.CO;2-U
M3 - Article
C2 - 7842413
AN - SCOPUS:0028801433
VL - 75
SP - 926
EP - 935
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 4
ER -